Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;163(3):868-874.
doi: 10.1002/ijgo.14998. Epub 2023 Jul 24.

Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma

Myriam Gracia  1 , Yusuf Yildirim  2 , Ronalds Macuks  3 , Rosanna Mancari  4   5 , Patriciu Achimas-Cadariu  6 , Laura Cusine-Lopez  7 , Zoltan Novak  8 , Kastriot Dallaku  9 , Ignacio Zapardiel  1 ; SARCUT Study Group
Affiliations

Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma

Myriam Gracia et al. Int J Gynaecol Obstet. 2023 Dec.

Abstract

Objectives: To analyze the impact of perioperative characteristics on the risk of recurrence in patients with uterine leiomyosarcomas.

Methods: A sub-analysis of the SARComa of the UTerus (SARCUT) study, which is a multicentric cross-sectional pan-European study that included 390 patients diagnosed with leiomyosarcoma, between 2001 and 2007. Perioperative factors related to risk of recurrence and survival were analyzed.

Results: The 5-year and 10-year disease-free survivals (DFS) were 46% and 55%, respectively. Overall survival at 5 and 10 years was 34% and 47%, respectively. The most important factors related to global recurrence were the incomplete cytoreduction (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.91-4.31); performing bilateral adnexectomy (HR 2.71; 95% CI 1.23-5.93); tumor persistence after any treatment (HR 2.38; 95% CI 1.39-4.06); and adjuvant chemotherapy administration (HR 2.55; 95% CI 1.82-3.58) or adjuvant radiotherapy (HR 2.26; 95% CI 1.53-3.32). The major factors significantly associated with pelvic relapse were tumor persistence after any treatment (HR 3.63; 95% CI 1.83-7.20) and adjuvant radiotherapy (HR 2.74; 95% CI 1.44-5.20). Incomplete cytoreduction was the most important factor associated with distant relapse (HR 1.91; 95% CI 1.22-2.97). The most important factors related to overall survival were tumor persistence after any treatment (HR 4.59; 95% CI 2.51-8.40), incomplete cytoreduction (HR 3.68; 95% CI 2.44-5.56), tumor margin involvement (HR 2.41; 95% CI 1.64-3.55) and adjuvant chemotherapy (HR 1.91; 95% CI 1.31-2.78).

Conclusions: Complete cytoreduction is the main prognosis factor impacting the DFS and overall survival of patients with uterine leiomyosarcoma. Adjuvant chemotherapy administration was associated with decreased rates of DFS and overall survival. The adjuvant radiotherapy was associated with a higher risk of global recurrence.

Keywords: cytoreductive surgery; prognostic factors; recurrence; survival; uterine leiomyosarcoma.

PubMed Disclaimer

References

REFERENCES

    1. Mbatani N, Olawaiye A, Prat J. Uterine sarcoma. Int J Gynaecol Obstet. 2018;143(2):51-58.
    1. Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151:562-572.
    1. Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145:61-70.
    1. Costales AB, Radeva M, Ricci S. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study. J Gynecol Oncol. 2020;31(3):e21.
    1. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820-830.

LinkOut - more resources